Global Minimally Invasive Glaucoma Surgery (MIGS) Devices Market Size, Share & Trends Analysis Report By Product (Valves, Glaucoma Drainage Implant), By Surgery Method, By End-use, By Region- Global Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2024-2033

The global minimally invasive glaucoma surgery (MIGS) devices market size was exhibited at USD 539.70 million in 2023 and is projected to hit around USD 910.59 million by 2033, growing at a CAGR of 5.37% during the forecast period of 2024 to 2033.

Key Takeaways:

• North America dominated the overall market in 2023.
• Based on end-use, the hospitals segment dominated the market in 2023.
• The glaucoma drainage implant segment held the largest market share of around 35.0% in 2023.
• The trabecular meshwork bypass segment accounted for the largest revenue share in 2023.

Market Overview

The Minimally Invasive Glaucoma Surgery (MIGS) devices market has experienced significant evolution over the past decade, emerging as a pivotal frontier in the treatment of glaucoma—a chronic eye condition affecting the optic nerve, often due to elevated intraocular pressure (IOP). As glaucoma remains the second leading cause of blindness worldwide, with the World Health Organization estimating that over 76 million people are affected globally, the need for safer, effective, and long-lasting surgical interventions has intensified.

Traditional surgical approaches such as trabeculectomy and tube shunt implantation, while effective, are associated with considerable postoperative risks including hypotony, infection, and scarring. MIGS devices were developed to overcome these limitations by offering safer alternatives with shorter recovery times and fewer complications. These devices are particularly designed for patients with mild to moderate open-angle glaucoma and are often combined with cataract surgeries, enhancing convenience and outcomes.

MIGS procedures involve minimal tissue disruption and typically target aqueous outflow pathways through trabecular meshwork bypass, Schlemm’s canal, suprachoroidal space, or subconjunctival space. The combination of safety, efficacy, and patient comfort has led to rapid adoption among ophthalmologists and growing preference among patients. Coupled with technological advancements, favorable reimbursement policies, and increased awareness, the MIGS devices market is poised for continued expansion.

Major Trends in the Market

• Combination with Cataract Surgery: MIGS procedures are increasingly being bundled with cataract surgeries, especially for elderly patients, reducing costs and surgical risks.

• Surge in Demand for Stent-based Devices: The market is witnessing a spike in the adoption of stents like the iStent and Hydrus Microstent due to their high efficacy in lowering IOP with minimal complications.

• Rise of Image-Guided and Robotic-assisted Surgeries: Advancements in surgical precision tools and visualization technologies are improving the safety and outcomes of MIGS procedures.

• Shift Towards Outpatient Procedures: The transition from inpatient to outpatient and ambulatory surgical settings is supporting the uptake of MIGS due to their minimal invasiveness.

• Growing Popularity of Gonioscopy-Assisted Procedures: Techniques like Gonioscopy-assisted Transluminal Trabeculectomy (GATT) are gaining traction due to their efficacy in managing complex glaucoma cases.

• Regulatory Expansions and Reimbursements: Improved reimbursement frameworks in North America and Europe are enabling broader patient access to MIGS devices.

• Surge in Targeted Innovation: Companies are developing devices customized for specific anatomical targets such as the Schlemm’s canal, to maximize pressure reduction while minimizing risks.

Minimally Invasive Glaucoma Surgery (MIGS) Devices Market Report Scope

Market Driver: Rising Geriatric Population and Glaucoma Incidence

The global surge in the elderly population is one of the strongest growth drivers for the MIGS devices market. Glaucoma prevalence increases significantly with age, with individuals above 60 being at much higher risk. As life expectancy rises across both developed and emerging economies, the incidence of primary open-angle glaucoma is expected to increase correspondingly.

For instance, in the United States, the National Eye Institute projects that the number of people with glaucoma will reach over 6.3 million by 2050. Similar trends are being observed in rapidly aging countries like Japan, Germany, and China. MIGS offers an ideal solution for elderly patients who are often reluctant or unable to undergo invasive surgical interventions due to comorbidities. The shorter recovery time, reduced complication rate, and the ability to combine with cataract surgeries make MIGS an optimal treatment modality for this demographic.

Market Restraint: Limited Long-Term Efficacy Data

Despite growing adoption, one of the major restraints in the MIGS devices market is the lack of comprehensive long-term efficacy data. Unlike traditional glaucoma surgeries that have decades of clinical follow-up and outcome studies, many MIGS devices are relatively new and lack robust longitudinal studies that validate their durability in managing IOP over extended periods.

This gap in evidence creates a challenge for both clinicians and insurers. Physicians may be hesitant to recommend MIGS for younger patients or advanced cases without clear long-term outcomes, while some payers may limit reimbursement due to insufficient cost-benefit analysis. This limits full-scale adoption, especially in conservative medical markets and public health systems that prioritize proven interventions.

Market Opportunity: Technological Integration with Smart Implants

A promising opportunity for the MIGS devices market lies in the integration of smart technologies, particularly IoT-enabled implants that can provide real-time intraocular pressure readings and alert patients or physicians to changes that warrant intervention. These advanced systems would not only offer IOP control but also facilitate disease monitoring, aligning with the broader shift toward precision medicine and personalized healthcare.

For instance, startups and R&D institutions are exploring implants embedded with sensors that transmit ocular pressure data to mobile applications. Such innovations could enable proactive glaucoma management, reduce the risk of blindness, and increase patient adherence to care protocols. As digital health infrastructure matures globally, this opportunity can significantly enhance the clinical value proposition of MIGS devices.

Segments Insights:

End-use Insights

Hospitals accounted for the largest market share in 2024, primarily due to the presence of highly specialized ophthalmic departments, access to advanced surgical infrastructure, and availability of skilled professionals. Patients with advanced or complicated glaucoma are often referred to tertiary care hospitals where comprehensive diagnostic and surgical capabilities are available. The ability to manage perioperative complications and provide post-surgical care under one roof further enhances hospital preference.

Additionally, hospitals are the primary beneficiaries of government reimbursements and bulk purchase agreements, which facilitates the acquisition of premium MIGS devices. These institutions also serve as key centers for clinical trials and academic research in glaucoma surgery.

Ophthalmic Clinics Fastest Growing with Shift Toward Ambulatory Care

Ophthalmic clinics are becoming the fastest-growing end-user segment in the MIGS market due to the increasing shift towards ambulatory and outpatient surgical care. These clinics offer same-day procedures, reduced hospital overhead, and improved patient convenience, particularly for uncomplicated glaucoma cases.

Driven by technological miniaturization and simplified surgical techniques, many MIGS procedures can now be performed in a clinic setting. Furthermore, the expansion of chain-based specialty eye care centers in countries like India, Australia, and Brazil is helping to broaden access to MIGS, particularly in underserved regions.

Product Insights

Stents emerged as the dominant product segment in the MIGS devices market, owing to their early introduction and proven efficacy in reducing intraocular pressure with minimal invasiveness. Devices like the iStent Inject (Glaukos) and Hydrus Microstent (Ivantis) have become first-line surgical choices for mild to moderate open-angle glaucoma. These devices enhance natural aqueous humor outflow by bypassing the trabecular meshwork and channeling fluid through Schlemm’s canal.

The widespread clinical adoption of stents is underpinned by ease of use, reduced postoperative complications, and compatibility with phacoemulsification during cataract surgery. Furthermore, stents enjoy better regulatory support and insurance coverage in developed nations, strengthening their market foothold. The growing number of trained ophthalmic surgeons specializing in stent implantation further contributes to the dominance of this segment.

While stents dominate, the glaucoma tube shunts segment is projected to be the fastest-growing category due to its expanding indications for complex and refractory glaucoma cases. Devices such as the Ahmed Glaucoma Valve and Baerveldt Glaucoma Implant are increasingly used in patients unresponsive to stents or medications. Their design allows for higher IOP reduction in patients with advanced disease.

Moreover, recent innovations in shunt materials and drainage mechanisms have enhanced biocompatibility and reduced the risk of encapsulation or erosion. The increasing burden of severe glaucoma in aging populations and rising familiarity among surgeons with these procedures support rapid growth in this segment.

Regional Insights

North America led the MIGS devices market in 2024, bolstered by its mature healthcare infrastructure, high glaucoma awareness, and early adoption of advanced surgical techniques. The United States, in particular, has been at the forefront of MIGS innovation, with companies like Glaukos, Ivantis, and Alcon playing pivotal roles in introducing and commercializing breakthrough devices.

The region benefits from comprehensive insurance coverage for several MIGS procedures, encouraging widespread clinical adoption. Additionally, a robust base of ophthalmic training institutions ensures that surgeons are well-versed in MIGS technologies, further driving market growth. Favorable FDA policies and the presence of major device manufacturers strengthen the region’s dominance.

Asia-Pacific is expected to exhibit the highest growth rate, driven by a rising geriatric population, expanding medical tourism, and increasing access to ophthalmic care. Countries like India and China are seeing a sharp increase in glaucoma diagnoses due to improved screening programs and health awareness campaigns. The push for early diagnosis and intervention is creating demand for less invasive and affordable surgical options, positioning MIGS devices favorably.

Furthermore, government initiatives to modernize healthcare infrastructure and the emergence of regional players focused on cost-effective devices are catalyzing the market. Academic collaborations and the establishment of glaucoma specialty centers in urban areas are accelerating procedural volumes.

Recent Developments

• Glaukos Corporation (March 2025): Announced the successful completion of a Phase III clinical trial for its iDose TR sustained-release drug delivery implant, aiming to combine pharmacotherapy with MIGS benefits.

• Alcon Inc. (February 2025): Received CE mark approval for its Hydrus Microstent 2.0, which features improved deployment mechanics and compatibility with advanced imaging systems.

• New World Medical (January 2025): Expanded its portfolio with the launch of Ahmed ClearPath, a next-gen glaucoma drainage device with enhanced surgical flexibility for complex cases.

• Santen Pharmaceutical (April 2025): Entered a collaboration with a Japanese robotics firm to develop an AI-guided MIGS implantation platform to improve surgical accuracy and reduce training time.

Some of the prominent players in the Minimally invasive glaucoma surgery (MIGS) devices market include:

• Alcon, Inc.
• Glaukos Corporation.
• Johnson & Johnson Vision
• AbbVie Inc. (Allergan Plc.)
• Corza Ophthalmology
• Carl Zeiss Meditec AG
• Katalyst Surgical
• Lumenis Ltd
• Ziemer Ophthalmic Systems AG
• Iridex Corporation

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the global minimally invasive glaucoma surgery (MIGS) devices market.

Product

• Valves
• Glaucoma Drainage Implant
• Glaucoma Tube Shunts
• Stents
• Others

Surgery Method

• Trabecular Meshwork Bypass

• • By Stent Placement
  • By Tissue Excision

• Suprachoroidal Space Implants
• Subconjunctival Space Implants
• Schlemm’s Canal Implants
• Gonioscopy-assisted Transluminal Trabeculectomy
• Endocyclophotocoagulation

End-use

• Hospitals
• Ophthalmic Clinics
• Others Surgical Centers

By Region

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East & Africa (MEA)